Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Предикция аденомиоза у больных с миомой матки
Предикция аденомиоза у больных с миомой матки
Шрамко С.В., Зорина В.Н., Власенко А.Е., Сабанцев М.А. Предикция аденомиоза у больных с миомой матки. Гинекология. 2023;25(1):49–54. DOI: 10.26442/20795696.2023.1.201802
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Определить клинико-анамнестические и иммунологические предикторы аденомиоза путем разработки прогностической модели миомы матки в сочетании с аденомиозом.
Материалы и методы. Ретроспективное одноцентровое исследование выполнено в условиях ГАУЗ «НГКБ №1 им. Г.П. Курбатова» с 2012 по 2019 г. В модель включены 284 женщины с гистологически подтвержденной миомой матки, из них в 34,9% (99/284) – миома сочеталась с аденомиозом и в 65,1% (185/284) – миома матки являлась «изолированной». Для построения математической модели использовалась логистическая регрессия.
Результаты. Предикторами аденомиоза у больных с миомой матки установлены возраст 43 года и старше, сопутствующая гиперплазия эндометрия, хронические воспалительные заболевания шейки матки, менометроррагия, наличие родов, патология эндометрия в анамнезе, варикозная болезнь вен нижних конечностей, аппендэктомия в анамнезе, содержание в сыворотке крови лактоферрина более 1,8 мг/л, интерлейкина-6 – более 2,8 пг/мл. Точность модели – 91%, чувствительность – 90%, специфичность – 92%, прогностическая ценность положительного результата – 85%, прогностическая ценность отрицательного результата – 94%.
Заключение. Установленные предикторы аденомиоза позволяют клиницистам прогнозировать риск развития и наличие аденомиоза у больных с миомой матки, облегчая выбор эффективной тактики лечения.
Ключевые слова: аденомиоз, миома матки, предикторы аденомиоза
Materials and methods. A retrospective single-center study was conducted at Kurbatov Novokuznetsk City Clinical Hospital №1, from 2012 to 2019. The model included 284 women with histologically confirmed uterine fibroids, of which 34.9% (99/284) were fibroids with adenomyosis and 65.1% (185/284) were “isolated” uterine fibroids. Logistic regression was used to develop the mathematical model.
Results. Predictors of adenomyosis in patients with uterine fibroids have been established: age 43 years and older, concomitant endometrial hyperplasia, chronic inflammatory diseases of the cervix, menometrorrhagia, history of childbirth, history of endometrial disorders, varicose veins of the lower extremities, history of appendectomy, blood serum lactoferrin of more than 1.8 mg/L, interleukin-6 levels more than 2.8 pg/mL. The model has an accuracy of 91%, a sensitivity of 90%, a specificity of 92%, a positive predictive value of 85%, and a negative predictive value of 94%.
Conclusion. The established predictors of adenomyosis allow for predicting the risk of adenomyosis in patients with uterine fibroids, facilitating effective treatment choices.
Keywords: adenomyosis, uterine fibroids, adenomyosis predictors
Материалы и методы. Ретроспективное одноцентровое исследование выполнено в условиях ГАУЗ «НГКБ №1 им. Г.П. Курбатова» с 2012 по 2019 г. В модель включены 284 женщины с гистологически подтвержденной миомой матки, из них в 34,9% (99/284) – миома сочеталась с аденомиозом и в 65,1% (185/284) – миома матки являлась «изолированной». Для построения математической модели использовалась логистическая регрессия.
Результаты. Предикторами аденомиоза у больных с миомой матки установлены возраст 43 года и старше, сопутствующая гиперплазия эндометрия, хронические воспалительные заболевания шейки матки, менометроррагия, наличие родов, патология эндометрия в анамнезе, варикозная болезнь вен нижних конечностей, аппендэктомия в анамнезе, содержание в сыворотке крови лактоферрина более 1,8 мг/л, интерлейкина-6 – более 2,8 пг/мл. Точность модели – 91%, чувствительность – 90%, специфичность – 92%, прогностическая ценность положительного результата – 85%, прогностическая ценность отрицательного результата – 94%.
Заключение. Установленные предикторы аденомиоза позволяют клиницистам прогнозировать риск развития и наличие аденомиоза у больных с миомой матки, облегчая выбор эффективной тактики лечения.
Ключевые слова: аденомиоз, миома матки, предикторы аденомиоза
________________________________________________
Materials and methods. A retrospective single-center study was conducted at Kurbatov Novokuznetsk City Clinical Hospital №1, from 2012 to 2019. The model included 284 women with histologically confirmed uterine fibroids, of which 34.9% (99/284) were fibroids with adenomyosis and 65.1% (185/284) were “isolated” uterine fibroids. Logistic regression was used to develop the mathematical model.
Results. Predictors of adenomyosis in patients with uterine fibroids have been established: age 43 years and older, concomitant endometrial hyperplasia, chronic inflammatory diseases of the cervix, menometrorrhagia, history of childbirth, history of endometrial disorders, varicose veins of the lower extremities, history of appendectomy, blood serum lactoferrin of more than 1.8 mg/L, interleukin-6 levels more than 2.8 pg/mL. The model has an accuracy of 91%, a sensitivity of 90%, a specificity of 92%, a positive predictive value of 85%, and a negative predictive value of 94%.
Conclusion. The established predictors of adenomyosis allow for predicting the risk of adenomyosis in patients with uterine fibroids, facilitating effective treatment choices.
Keywords: adenomyosis, uterine fibroids, adenomyosis predictors
Полный текст
Список литературы
1. Abbott JA. Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol. 2017;40:68-81. DOI:10.1016/j.bpobgyn.2016.09.006
2. Эл-Джефут М., Артымук Н.В. Новое о теориях патогенеза эндометриоза. Фундаментальная и клиническая медицина. 2019;4(3):77-82 [Al-Jefout M, Artymuk NV. Causes and mechanisms of endometriosis: an update. Fundamental and Clinical Medicine. 2019;4(3):77-82 (in Russian)]. DOI:10.23946/2500-0764-2019-4-3-77-82
3. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
4. Tanos V, Lingwood L, Balami S. Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. Gynecol Obstet Invest. 2020;85(2):107-17. DOI:10.1159/000505650
5. Yu O, Schulze-Rath R, Grafton J, et al. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020;223(1):94.e1-10. DOI:10.1016/j.ajog.2020.01.016
6. Эндометриоз. Клинические рекомендации Минздрава РФ. M., 2020 [Endometrioz. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian)].
7. Миома матки. Клинические рекомендации Минздрава РФ. M., 2020 [Mioma matki. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian)].
8. Xiang Y, Sun Y, Yang B, et al. Transcriptome sequencing of adenomyosis eutopic endometrium: A new insight into its pathophysiology. J Cell Mol Med. 2019;23(12):8381-91. DOI:10.1111/jcmm.14718
9. Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785. DOI:10.1038/s41467-019-13708-y
10. Tanos V, Balami S, Lingwood L. Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Curr Opin Obstet Gynecol. 2019;31(6):418-27. DOI:10.1097/GCO.0000000000000572
11. Guo SW. The Pathogenesis of Adenomyosis vis-à-vis Endometriosis. J Clin Med. 2020;9(2):485. DOI:10.3390/jcm9020485
12. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
13. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086-97. DOI:10.1093/humupd/dmab017
14. Тихончук Е.Ю., Асатурова А.В., Адамян Л.В. Молекулярно-биологические изменения эндометрия у женщин с наружным генитальным эндометриозом. Акушерство и гинекология. 2016;11:42-8 [Tihonchuk EYu, Asaturova AV, Adamyan LV. Molekulyarno-biologicheskie izmeneniya endometriya u zhenshchin s naruzhnym genital'nym endometriozom. Obstetrics and Gynecology. 2016;11:42-8 (in Russian)]. DOI:10.18565/aig.2016.11.42-8
15. Дамиров М.М., Белозеров Г.Е., Олейникова О.Н. Современные подходы к эмболизации маточных артерий в лечении лейомиомы матки (обзор литературы). Гинекология. 2015;17(2):65-9 [Damirov MM, Belozerov GE, Oleynikova ON. Modern approaches to uterine artery embolization in the treatment of uterine leiomyoma(review). Gynecology. 2015;17(2):65-9 (in Russian)].
16. Huang YQ, Zhou SG, Wang J, et al. [Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study. Zhonghua Yi Xue Za Zhi. 2019;99(15):1152-5 (in Chinese)]. DOI:10.3760/cma.j.issn.0376-2491.2019.15.007
17. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-68. DOI:10.1093/humrep/det050
18. Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-70. DOI:10.1093/humupd/dmq042
19. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-78. DOI:10.1016/S1701-2163(15)30338-8
20. Andres MP, Borrelli GM, Ribeiro J, et al. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 201;25(2):257-64. DOI:10.1016/j.jmig.2017.08.653
21. Sam M, Raubenheimer M, Manolea F, et al. Accuracy of findings in the diagnosis of uterine adenomyosis on ultrasound. Abdom Radiol (NY). 2020;45(3):842-50.
DOI:10.1007/s00261-019-02231-9
22. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-12. DOI:10.1093/humrep/det457
23. Tellum T, Nygaard S, Skovholt EK, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018;110(5):957-64.e3. DOI:10.1016/j.fertnstert.2018.06.009
24. Jiang C, Liu C, Guo J, et al. CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion. Medicine (Baltimore). 2017;96(19):e6880. DOI:10.1097/MD.0000000000006880
25. Bodur S, Gün I, Alpaslan Babayigit M. The significance of mean platelet volume on diagnosis and management of adenomyosis. Med Glas (Zenica). 2013;10(1):59-62.
26. Özkan ZS, Kumbak B, Cilgin H, et al. Coexistence of adenomyosis in women operated for benign gynecological diseases. Gynecol Endocrinol. 2012;28(3):212-5. DOI:10.3109/09513590.2011.593669
27. Vavilis D, Agorastos T, Tzafetas J, et al. Adenomyosis at hysterectomy: prevalence and relationship to operative findings and reproductive and menstrual factors. Clin Exp Obstet Gynecol. 1997;24(1):36-8.
28. Оразов М.Р., Радзинский В.Е., Носенко Е.Н. Роль иммуновоспалительной реактивности в развитии болевого синдрома при аденомиозе. Патологическая физиология и экспериментальная терапия. 2016;60(1):40-4 [Orazov MR, Radzinskiy VE, Nosenko OM. The role of inflammatory and immune reactivity in developing pain in adenomyosis. Patologicheskaya fisiologiya i eksperimentalnaya terapiya. 2016;60(1):40-4 (in Russian)].
29. Беженарь В.Ф., Линдэ В.А., Аракелян Б.В., и др. Аденомиоз и фертильность: современный взгляд на проблему (обзор литературы). Журнал акушерства и женских болезней. 2022;71(1):109-18 [Bezhenar VF, Linde VA, Arakelyan BV, et al. Adenomyosis and fertility: a modern view of the problem. A literature review. Journal of obstetrics and women's diseases. 2022;71(1):109-18 (in Russian)]. DOI:10.17816/JOWD78939
30. Ecker AM, Chamsy D, Austin RM, et al. Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. J Gynecol Surg. 2018;34(4):183-9. DOI:10.1089/gyn.2017.0112
31. Taran FA, Wallwiener M, Kabashi D, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012;285(6):1571-6. DOI:10.1007/s00404-011-2180-7
32. Filip G, Balzano A, Cagnacci A. Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. Minerva Ginecol. 2019;71(3):177-81. DOI:10.23736/S0026-4784.18.04291-0
33. Ates S, Ozcan P, Aydin S, Karaca N. Differences in clinical characteristics for the determination of adenomyosis coexisting with leiomyomas. J Obstet Gynaecol Res. 2016;42(3):307-12. DOI:10.1111/jog.12905
34. Bazot M, Thomassin-Naggara I, Daraj E, Marsault C. Imaging of chronic pelvis pain. J Radiol. 2008;89(1 Pt 2):107-14.
35. Smol'nova TIu. Features hemodynamics and its relationship with some clinical manifestations in women with connective tissue dysplasia. Klin Med (Mosk). 2013;91(10):43-8 (in Russian)].
36. Kaderli R. Incidental appendectomy: standard or unjustified risk? Ther Umsch. 2014;71(12):753-8 (in German). DOI:10.1024/0040-5930/a000621
2. Al-Jefout M, Artymuk NV. Causes and mechanisms of endometriosis: an update. Fundamental and Clinical Medicine. 2019;4(3):77-82 (in Russian). DOI:10.23946/2500-0764-2019-4-3-77-82
3. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
4. Tanos V, Lingwood L, Balami S. Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. Gynecol Obstet Invest. 2020;85(2):107-17. DOI:10.1159/000505650
5. Yu O, Schulze-Rath R, Grafton J, et al. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020;223(1):94.e1-10. DOI:10.1016/j.ajog.2020.01.016
6. Endometrioz. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian).
7. Mioma matki. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian).
8. Xiang Y, Sun Y, Yang B, et al. Transcriptome sequencing of adenomyosis eutopic endometrium: A new insight into its pathophysiology. J Cell Mol Med. 2019;23(12):8381-91. DOI:10.1111/jcmm.14718
9. Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785. DOI:10.1038/s41467-019-13708-y
10. Tanos V, Balami S, Lingwood L. Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Curr Opin Obstet Gynecol. 2019;31(6):418-27. DOI:10.1097/GCO.0000000000000572
11. Guo SW. The Pathogenesis of Adenomyosis vis-à-vis Endometriosis. J Clin Med. 2020;9(2):485. DOI:10.3390/jcm9020485
12. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
13. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086-97. DOI:10.1093/humupd/dmab017
14. Tihonchuk EYu, Asaturova AV, Adamyan LV. Molekulyarno-biologicheskie izmeneniya endometriya u zhenshchin s naruzhnym genital'nym endometriozom. Obstetrics and Gynecology. 2016;11:42-8 (in Russian). DOI:10.18565/aig.2016.11.42-8
15. Damirov MM, Belozerov GE, Oleynikova ON. Modern approaches to uterine artery embolization in the treatment of uterine leiomyoma(review). Gynecology. 2015;17(2):65-9 (in Russian).
16. Huang YQ, Zhou SG, Wang J, et al. [Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study. Zhonghua Yi Xue Za Zhi. 2019;99(15):1152-5 (in Chinese)]. DOI:10.3760/cma.j.issn.0376-2491.2019.15.007
17. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-68. DOI:10.1093/humrep/det050
18. Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-70. DOI:10.1093/humupd/dmq042
19. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-78. DOI:10.1016/S1701-2163(15)30338-8
20. Andres MP, Borrelli GM, Ribeiro J, et al. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 201;25(2):257-64. DOI:10.1016/j.jmig.2017.08.653
21. Sam M, Raubenheimer M, Manolea F, et al. Accuracy of findings in the diagnosis of uterine adenomyosis on ultrasound. Abdom Radiol (NY). 2020;45(3):842-50.
DOI:10.1007/s00261-019-02231-9
22. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-12. DOI:10.1093/humrep/det457
23. Tellum T, Nygaard S, Skovholt EK, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018;110(5):957-64.e3. DOI:10.1016/j.fertnstert.2018.06.009
24. Jiang C, Liu C, Guo J, et al. CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion. Medicine (Baltimore). 2017;96(19):e6880. DOI:10.1097/MD.0000000000006880
25. Bodur S, Gün I, Alpaslan Babayigit M. The significance of mean platelet volume on diagnosis and management of adenomyosis. Med Glas (Zenica). 2013;10(1):59-62.
26. Özkan ZS, Kumbak B, Cilgin H, et al. Coexistence of adenomyosis in women operated for benign gynecological diseases. Gynecol Endocrinol. 2012;28(3):212-5. DOI:10.3109/09513590.2011.593669
27. Vavilis D, Agorastos T, Tzafetas J, et al. Adenomyosis at hysterectomy: prevalence and relationship to operative findings and reproductive and menstrual factors. Clin Exp Obstet Gynecol. 1997;24(1):36-8.
28. Orazov MR, Radzinskiy VE, Nosenko OM. The role of inflammatory and immune reactivity in developing pain in adenomyosis. Patologicheskaya fisiologiya i eksperimentalnaya terapiya. 2016;60(1):40-4 (in Russian).
29. Bezhenar VF, Linde VA, Arakelyan BV, et al. Adenomyosis and fertility: a modern view of the problem. A literature review. Journal of obstetrics and women's diseases. 2022;71(1):109-18 (in Russian). DOI:10.17816/JOWD78939
30. Ecker AM, Chamsy D, Austin RM, et al. Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. J Gynecol Surg. 2018;34(4):183-9. DOI:10.1089/gyn.2017.0112
31. Taran FA, Wallwiener M, Kabashi D, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012;285(6):1571-6. DOI:10.1007/s00404-011-2180-7
32. Filip G, Balzano A, Cagnacci A. Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. Minerva Ginecol. 2019;71(3):177-81. DOI:10.23736/S0026-4784.18.04291-0
33. Ates S, Ozcan P, Aydin S, Karaca N. Differences in clinical characteristics for the determination of adenomyosis coexisting with leiomyomas. J Obstet Gynaecol Res. 2016;42(3):307-12. DOI:10.1111/jog.12905
34. Bazot M, Thomassin-Naggara I, Daraj E, Marsault C. Imaging of chronic pelvis pain. J Radiol. 2008;89(1 Pt 2):107-14.
35. Smol'nova TIu. Features hemodynamics and its relationship with some clinical manifestations in women with connective tissue dysplasia. Klin Med (Mosk). 2013;91(10):43-8 (in Russian)].
36. Kaderli R. Incidental appendectomy: standard or unjustified risk? Ther Umsch. 2014;71(12):753-8 (in German). DOI:10.1024/0040-5930/a000621
2. Эл-Джефут М., Артымук Н.В. Новое о теориях патогенеза эндометриоза. Фундаментальная и клиническая медицина. 2019;4(3):77-82 [Al-Jefout M, Artymuk NV. Causes and mechanisms of endometriosis: an update. Fundamental and Clinical Medicine. 2019;4(3):77-82 (in Russian)]. DOI:10.23946/2500-0764-2019-4-3-77-82
3. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
4. Tanos V, Lingwood L, Balami S. Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. Gynecol Obstet Invest. 2020;85(2):107-17. DOI:10.1159/000505650
5. Yu O, Schulze-Rath R, Grafton J, et al. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020;223(1):94.e1-10. DOI:10.1016/j.ajog.2020.01.016
6. Эндометриоз. Клинические рекомендации Минздрава РФ. M., 2020 [Endometrioz. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian)].
7. Миома матки. Клинические рекомендации Минздрава РФ. M., 2020 [Mioma matki. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian)].
8. Xiang Y, Sun Y, Yang B, et al. Transcriptome sequencing of adenomyosis eutopic endometrium: A new insight into its pathophysiology. J Cell Mol Med. 2019;23(12):8381-91. DOI:10.1111/jcmm.14718
9. Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785. DOI:10.1038/s41467-019-13708-y
10. Tanos V, Balami S, Lingwood L. Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Curr Opin Obstet Gynecol. 2019;31(6):418-27. DOI:10.1097/GCO.0000000000000572
11. Guo SW. The Pathogenesis of Adenomyosis vis-à-vis Endometriosis. J Clin Med. 2020;9(2):485. DOI:10.3390/jcm9020485
12. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
13. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086-97. DOI:10.1093/humupd/dmab017
14. Тихончук Е.Ю., Асатурова А.В., Адамян Л.В. Молекулярно-биологические изменения эндометрия у женщин с наружным генитальным эндометриозом. Акушерство и гинекология. 2016;11:42-8 [Tihonchuk EYu, Asaturova AV, Adamyan LV. Molekulyarno-biologicheskie izmeneniya endometriya u zhenshchin s naruzhnym genital'nym endometriozom. Obstetrics and Gynecology. 2016;11:42-8 (in Russian)]. DOI:10.18565/aig.2016.11.42-8
15. Дамиров М.М., Белозеров Г.Е., Олейникова О.Н. Современные подходы к эмболизации маточных артерий в лечении лейомиомы матки (обзор литературы). Гинекология. 2015;17(2):65-9 [Damirov MM, Belozerov GE, Oleynikova ON. Modern approaches to uterine artery embolization in the treatment of uterine leiomyoma(review). Gynecology. 2015;17(2):65-9 (in Russian)].
16. Huang YQ, Zhou SG, Wang J, et al. [Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study. Zhonghua Yi Xue Za Zhi. 2019;99(15):1152-5 (in Chinese)]. DOI:10.3760/cma.j.issn.0376-2491.2019.15.007
17. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-68. DOI:10.1093/humrep/det050
18. Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-70. DOI:10.1093/humupd/dmq042
19. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-78. DOI:10.1016/S1701-2163(15)30338-8
20. Andres MP, Borrelli GM, Ribeiro J, et al. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 201;25(2):257-64. DOI:10.1016/j.jmig.2017.08.653
21. Sam M, Raubenheimer M, Manolea F, et al. Accuracy of findings in the diagnosis of uterine adenomyosis on ultrasound. Abdom Radiol (NY). 2020;45(3):842-50.
DOI:10.1007/s00261-019-02231-9
22. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-12. DOI:10.1093/humrep/det457
23. Tellum T, Nygaard S, Skovholt EK, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018;110(5):957-64.e3. DOI:10.1016/j.fertnstert.2018.06.009
24. Jiang C, Liu C, Guo J, et al. CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion. Medicine (Baltimore). 2017;96(19):e6880. DOI:10.1097/MD.0000000000006880
25. Bodur S, Gün I, Alpaslan Babayigit M. The significance of mean platelet volume on diagnosis and management of adenomyosis. Med Glas (Zenica). 2013;10(1):59-62.
26. Özkan ZS, Kumbak B, Cilgin H, et al. Coexistence of adenomyosis in women operated for benign gynecological diseases. Gynecol Endocrinol. 2012;28(3):212-5. DOI:10.3109/09513590.2011.593669
27. Vavilis D, Agorastos T, Tzafetas J, et al. Adenomyosis at hysterectomy: prevalence and relationship to operative findings and reproductive and menstrual factors. Clin Exp Obstet Gynecol. 1997;24(1):36-8.
28. Оразов М.Р., Радзинский В.Е., Носенко Е.Н. Роль иммуновоспалительной реактивности в развитии болевого синдрома при аденомиозе. Патологическая физиология и экспериментальная терапия. 2016;60(1):40-4 [Orazov MR, Radzinskiy VE, Nosenko OM. The role of inflammatory and immune reactivity in developing pain in adenomyosis. Patologicheskaya fisiologiya i eksperimentalnaya terapiya. 2016;60(1):40-4 (in Russian)].
29. Беженарь В.Ф., Линдэ В.А., Аракелян Б.В., и др. Аденомиоз и фертильность: современный взгляд на проблему (обзор литературы). Журнал акушерства и женских болезней. 2022;71(1):109-18 [Bezhenar VF, Linde VA, Arakelyan BV, et al. Adenomyosis and fertility: a modern view of the problem. A literature review. Journal of obstetrics and women's diseases. 2022;71(1):109-18 (in Russian)]. DOI:10.17816/JOWD78939
30. Ecker AM, Chamsy D, Austin RM, et al. Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. J Gynecol Surg. 2018;34(4):183-9. DOI:10.1089/gyn.2017.0112
31. Taran FA, Wallwiener M, Kabashi D, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012;285(6):1571-6. DOI:10.1007/s00404-011-2180-7
32. Filip G, Balzano A, Cagnacci A. Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. Minerva Ginecol. 2019;71(3):177-81. DOI:10.23736/S0026-4784.18.04291-0
33. Ates S, Ozcan P, Aydin S, Karaca N. Differences in clinical characteristics for the determination of adenomyosis coexisting with leiomyomas. J Obstet Gynaecol Res. 2016;42(3):307-12. DOI:10.1111/jog.12905
34. Bazot M, Thomassin-Naggara I, Daraj E, Marsault C. Imaging of chronic pelvis pain. J Radiol. 2008;89(1 Pt 2):107-14.
35. Smol'nova TIu. Features hemodynamics and its relationship with some clinical manifestations in women with connective tissue dysplasia. Klin Med (Mosk). 2013;91(10):43-8 (in Russian)].
36. Kaderli R. Incidental appendectomy: standard or unjustified risk? Ther Umsch. 2014;71(12):753-8 (in German). DOI:10.1024/0040-5930/a000621
________________________________________________
2. Al-Jefout M, Artymuk NV. Causes and mechanisms of endometriosis: an update. Fundamental and Clinical Medicine. 2019;4(3):77-82 (in Russian). DOI:10.23946/2500-0764-2019-4-3-77-82
3. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8:F1000 Faculty Rev-283. DOI:10.12688/f1000research.17242.1
4. Tanos V, Lingwood L, Balami S. Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. Gynecol Obstet Invest. 2020;85(2):107-17. DOI:10.1159/000505650
5. Yu O, Schulze-Rath R, Grafton J, et al. Adenomyosis incidence, prevalence and treatment: United States population-based study 2006-2015. Am J Obstet Gynecol. 2020;223(1):94.e1-10. DOI:10.1016/j.ajog.2020.01.016
6. Endometrioz. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian).
7. Mioma matki. Klinicheskiie rekomendatsii Minzdrava RF. Moscow, 2020 (in Russian).
8. Xiang Y, Sun Y, Yang B, et al. Transcriptome sequencing of adenomyosis eutopic endometrium: A new insight into its pathophysiology. J Cell Mol Med. 2019;23(12):8381-91. DOI:10.1111/jcmm.14718
9. Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785. DOI:10.1038/s41467-019-13708-y
10. Tanos V, Balami S, Lingwood L. Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Curr Opin Obstet Gynecol. 2019;31(6):418-27. DOI:10.1097/GCO.0000000000000572
11. Guo SW. The Pathogenesis of Adenomyosis vis-à-vis Endometriosis. J Clin Med. 2020;9(2):485. DOI:10.3390/jcm9020485
12. Rathinam KK, Abraham JJ, S HP, et al. Evaluation of pharmacological interventions in the management of adenomyosis: a systematic review. Eur J Clin Pharmacol. 2022;78(4):531-45. DOI:10.1007/s00228-021-03256-0
13. Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086-97. DOI:10.1093/humupd/dmab017
14. Tihonchuk EYu, Asaturova AV, Adamyan LV. Molekulyarno-biologicheskie izmeneniya endometriya u zhenshchin s naruzhnym genital'nym endometriozom. Obstetrics and Gynecology. 2016;11:42-8 (in Russian). DOI:10.18565/aig.2016.11.42-8
15. Damirov MM, Belozerov GE, Oleynikova ON. Modern approaches to uterine artery embolization in the treatment of uterine leiomyoma(review). Gynecology. 2015;17(2):65-9 (in Russian).
16. Huang YQ, Zhou SG, Wang J, et al. [Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study. Zhonghua Yi Xue Za Zhi. 2019;99(15):1152-5 (in Chinese)]. DOI:10.3760/cma.j.issn.0376-2491.2019.15.007
17. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-68. DOI:10.1093/humrep/det050
18. Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update. 2011;17(2):159-70. DOI:10.1093/humupd/dmq042
19. Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-78. DOI:10.1016/S1701-2163(15)30338-8
20. Andres MP, Borrelli GM, Ribeiro J, et al. Transvaginal Ultrasound for the Diagnosis of Adenomyosis: Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 201;25(2):257-64. DOI:10.1016/j.jmig.2017.08.653
21. Sam M, Raubenheimer M, Manolea F, et al. Accuracy of findings in the diagnosis of uterine adenomyosis on ultrasound. Abdom Radiol (NY). 2020;45(3):842-50.
DOI:10.1007/s00261-019-02231-9
22. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400-12. DOI:10.1093/humrep/det457
23. Tellum T, Nygaard S, Skovholt EK, et al. Development of a clinical prediction model for diagnosing adenomyosis. Fertil Steril. 2018;110(5):957-64.e3. DOI:10.1016/j.fertnstert.2018.06.009
24. Jiang C, Liu C, Guo J, et al. CA125 modified by PLT and NLR improves the predictive accuracy of adenomyosis-derived pelvic dense adhesion. Medicine (Baltimore). 2017;96(19):e6880. DOI:10.1097/MD.0000000000006880
25. Bodur S, Gün I, Alpaslan Babayigit M. The significance of mean platelet volume on diagnosis and management of adenomyosis. Med Glas (Zenica). 2013;10(1):59-62.
26. Özkan ZS, Kumbak B, Cilgin H, et al. Coexistence of adenomyosis in women operated for benign gynecological diseases. Gynecol Endocrinol. 2012;28(3):212-5. DOI:10.3109/09513590.2011.593669
27. Vavilis D, Agorastos T, Tzafetas J, et al. Adenomyosis at hysterectomy: prevalence and relationship to operative findings and reproductive and menstrual factors. Clin Exp Obstet Gynecol. 1997;24(1):36-8.
28. Orazov MR, Radzinskiy VE, Nosenko OM. The role of inflammatory and immune reactivity in developing pain in adenomyosis. Patologicheskaya fisiologiya i eksperimentalnaya terapiya. 2016;60(1):40-4 (in Russian).
29. Bezhenar VF, Linde VA, Arakelyan BV, et al. Adenomyosis and fertility: a modern view of the problem. A literature review. Journal of obstetrics and women's diseases. 2022;71(1):109-18 (in Russian). DOI:10.17816/JOWD78939
30. Ecker AM, Chamsy D, Austin RM, et al. Use of Uterine Characteristics to Improve Fertility-Sparing Diagnosis of Adenomyosis. J Gynecol Surg. 2018;34(4):183-9. DOI:10.1089/gyn.2017.0112
31. Taran FA, Wallwiener M, Kabashi D, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2012;285(6):1571-6. DOI:10.1007/s00404-011-2180-7
32. Filip G, Balzano A, Cagnacci A. Histological evaluation of the prevalence of adenomyosis, myomas and of their concomitance. Minerva Ginecol. 2019;71(3):177-81. DOI:10.23736/S0026-4784.18.04291-0
33. Ates S, Ozcan P, Aydin S, Karaca N. Differences in clinical characteristics for the determination of adenomyosis coexisting with leiomyomas. J Obstet Gynaecol Res. 2016;42(3):307-12. DOI:10.1111/jog.12905
34. Bazot M, Thomassin-Naggara I, Daraj E, Marsault C. Imaging of chronic pelvis pain. J Radiol. 2008;89(1 Pt 2):107-14.
35. Smol'nova TIu. Features hemodynamics and its relationship with some clinical manifestations in women with connective tissue dysplasia. Klin Med (Mosk). 2013;91(10):43-8 (in Russian)].
36. Kaderli R. Incidental appendectomy: standard or unjustified risk? Ther Umsch. 2014;71(12):753-8 (in German). DOI:10.1024/0040-5930/a000621
Авторы
С.В. Шрамко1, В.Н. Зорина2, А.Е. Власенко1, М.А. Сабанцев*3
1 Новокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Новокузнецк, Россия;
2 ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России, Санкт- Петербург, Россия;
3 ГАУЗ «Новокузнецкая городская клиническая больница №1 им. Г.П. Курбатова», Новокузнецк, Россия
*Dr.Sabantsev@ya.ru
1 Novokuznetsk State Institute of Postgraduate Medical Education – Branch of the Russian Medical Academy of Continuous Professional Education, Novokuznetsk, Russia;
2 State Research Institute of Highly Pure Biopreparations, Saint Petersburg, Russia;
3 Kurbatov Novokuznetsk City Clinical Hospital №1, Novokuznetsk, Russia
*Dr.Sabantsev@ya.ru
1 Новокузнецкий государственный институт усовершенствования врачей – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Новокузнецк, Россия;
2 ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России, Санкт- Петербург, Россия;
3 ГАУЗ «Новокузнецкая городская клиническая больница №1 им. Г.П. Курбатова», Новокузнецк, Россия
*Dr.Sabantsev@ya.ru
________________________________________________
1 Novokuznetsk State Institute of Postgraduate Medical Education – Branch of the Russian Medical Academy of Continuous Professional Education, Novokuznetsk, Russia;
2 State Research Institute of Highly Pure Biopreparations, Saint Petersburg, Russia;
3 Kurbatov Novokuznetsk City Clinical Hospital №1, Novokuznetsk, Russia
*Dr.Sabantsev@ya.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.